Functional genomics for rational tumor and immune cell combination therapy

Notwithstanding clinical advances, unfortunately many patients are not experiencing durably benefit from targeted and immunotherapies, mostly because of early or late resistance. We employ function-based, genome-wide screens and other strategies to develop rational combinatorial cancer treatment, targeting both cancer and immune cells.

On the one hand, we’re increasing our understanding of how cancer cells rewire their signaling networks, to expose and exploit new pharmacologically tractable tumor susceptibilities, particularly in the context of immunotherapy. On the other hand, we’re manipulating various cell types from the patient’s own immune system to revert their dysfunction and boost their specific cytotoxicity towards tumor cells. We complement these studies with analyses of clinical samples in collaboration with our clinical colleagues.

In this way, we develop new rational combinatorial therapies, which simultaneously eliminate the patients’ tumors and harness their immune system, aiming to achieve more durable clinical responses. Below are some of our recent highlights, including published studies and newly obtained grants.

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.